GTPase KRAS mutant inhibitors divulged in Shouyao Holdings patent
AI Briefing
- Researchers at Shouyao Holdings discovered new GTPase KRAS mutant inhibitors for cancer treatment.
- The inhibitors target specific cancer-causing KRAS mutations.
- Potential therapeutic applications are being explored for these mutant inhibitors.
Source Summary
Work at Shouyao Holdings (Beijing) Co. Ltd. has led to the identification of new GTPase KRAS mutant inhibitors potentially useful for the treatment of cancer.
Advertisement